---
schema_version: "secwatch.filing_event.v1"
accession: "0001933414-24-000044"
form_type: "8-K"
ticker: "MLYS"
cik: "0001933414"
company_name: "Mineralys Therapeutics, Inc."
filed_at: "2024-09-25T23:59:59+00:00"
generated_at: "2026-05-31T01:56:17.901257+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Mineralys completes enrollment of 261 subjects in pivotal Advance-HTN trial; topline Q1 2025

## Summary
- Target enrollment of 261 subjects achieved in Phase 2 Advance-HTN trial of lorundrostat for uncontrolled or resistant hypertension.
- Topline data expected Q1 2025; additional subjects in screening may enroll over next several weeks.
- Trial is randomized, double-blind, placebo-controlled, add-on to standardized antihypertensive regimen.
- Virtual KOL event scheduled for October 30, 2024 to discuss unmet need and clinical program.

## SEC filing metadata
- accession: 0001933414-24-000044
- form_type: 8-K
- ticker: MLYS
- cik: 0001933414
- company_name: Mineralys Therapeutics, Inc.
- filed_at: 2024-09-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1933414/000193341424000044/0001933414-24-000044-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1933414/000193341424000044/mlys-20240925.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001933414-24-000044
- JSON: https://secwatch.observer/filing/0001933414-24-000044.json
- Plain text: https://secwatch.observer/filing/0001933414-24-000044.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.